CSIMarket Company Name, Ticker, Customers, else..
 
Soligenix inc   (NASDAQ: SNGX)
Other Ticker:  
 
 
Price: $3.3371 $0.04 1.124%
Day's High: $3.3371 Week Perf: -1.85 %
Day's Low: $ 3.34 30 Day Perf: -3.83 %
Volume (M): 1 52 Wk High: $ 19.20
Volume (M$): $ 2 52 Wk Avg: $6.45
Open: $3.34 52 Wk Low: $1.83



 Market Capitalization (Millions $) 7
 Shares Outstanding (Millions) 2
 Employees 14
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -7
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Soligenix Inc
Soligenix, Inc. is a biopharmaceutical company that focuses on developing and commercializing products to treat rare diseases with unmet medical needs. The company primarily works on developing therapies for areas such as inflammation, oncology, and infectious diseases. Soligenix's main product candidates include a vaccine for the prevention of ricin toxin exposure (RiVax'), a treatment for oral mucositis in head and neck cancer patients (SGX942), and a treatment for pediatric Crohn's disease (SGX203). The company also has a proprietary technology platform called Dusquetide, which enhances the efficacy of existing drugs. Soligenix is headquartered in Princeton, New Jersey, and was founded in 198


   Company Address: 29 EMMONS DRIVE PRINCETON, 8540 NJ
   Company Phone Number: 538-8200   Stock Exchange / Ticker: NASDAQ SNGX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALNY      % 
BMY   -5.14%    
EBS   -3.52%    
REGN   -6.94%    
SRPT   -4.76%    
VRTX        0.44% 
• View Complete Report
   



Stocks on the Move

Soligenix Secures Exciting Results for HyBryte in CTCL Study, Boosting Valuation to $35

Published Tue, Jul 16 2024 8:41 AM UTC

Soligenix Inc. (NASDAQ:SNGX) recently unveiled positive interim results from an investigator-initiated study involving HyBryte, a potential treatment for Cutaneous T-Cell Lymphoma (CTCL). The encouraging findings have propelled the company s valuation to an impressive $35, reflecting the market s optimism towards Soligenix s groundbreaking research.The study, which evaluated...
Stocks on the Move

Soligenix Inc A Promising Outlook and Positive Study Results Propelling Growth in the Pharmaceutical Industry

Published Fri, Jun 28 2024 4:55 AM UTC

In the dynamic landscape of the pharmaceutical industry, Soligenix Inc (NASDAQ: SNGX) has emerged as a prominent player, garnering attention from industry analysts and investors alike. This article explores recent developments surrounding Soligenix Inc, including a positive growth outlook and groundbreaking study results that are propelling the company forward. With a focus ...
Soligenix Inc

2. Investors in the Dark: Uncertainty Looms Over Soligenix Inc's Futurelineno performance



Soligenix Inc, a late-stage biopharmaceutical company dedicated to developing and commercializing treatments for rare diseases, recently released its financial results for the first quarter of 2024. The company's shares experienced a downturn in May, and its year-to-date performance displays concerning figures. Additionally, Soligenix Inc trades only slightly above its 52-week low. These results raise questions regarding how these factors will impact the company's future prospects.
1. Declining Share Performance:
Soligenix Inc shares experienced a 2.15% decline over the course of May, exacerbating the company's year-to-date performance, which sits at a worrying -52.41%. Such a decline signals a lack of investor confidence in the company's financial stability and growth potential. Investors may be wary of the potential risks associated with Soligenix Inc's ongoing operations and its ability to generate sustainable revenue.
Soligenix Inc

Soligenix Inc Narrows Fourth Quarter Shortfall 2.

As a financial journalist for the , I have been closely following the recent financial results of Major Pharmaceutical Preparations company, Soligenix Inc. The company's performance in the October to December 31, 2023 period has shown some improvement compared to the previous year.
In the fourth quarter of 2023, Soligenix Inc reported a net shortfall of $-1.820 million, a significant improvement from the $-11.901 million deficit in the same quarter a year ago. The company also managed to reduce its shortfall per share to $-0.17 from $-4.14 in the previous year, indicating progress in their financial performance.
Despite the positive changes, Soligenix Inc's revenue deteriorated by -11.55% from $0.95 million in the previous year. However, in the recent quarter, revenue surged by 87.682% from $0.13 million in the prior quarter, showing a promising trend for the company's future financial performance.
Soligenix Inc

Soligenix Inc witnesses an impressive revenue surge in Q1 2023, showcasing robust growth

Soligenix Inc is a healthcare company that has recently released its fiscal period financial results. These results show that the company experienced a significant increase in diminishing returns, with a per share value of -$0.36, compared to -$0.06 in the previous year. However, the company's EPS improved from -$4.14 per share in the preceding reporting season.
One positive aspect of Soligenix Inc's financial performance is the strong growth in revenue, which rose by 74.248% to $0.26 million from $0.15 million in the same reporting season a year prior. Additionally, the company's revenue turned positive from -$1,772.95 million sequentially. Despite these improvements, Soligenix Inc realized a net shortfall of -$1.046 million in the most recent fiscal period, instead of achieving balanced books as it did in the same reporting season a year before.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com